

Resource Summary Report

Generated by [RRID](#) on Aug 1, 2026

ErbB-4 (C-18)

RRID:AB_2231308

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-283, RRID:AB_2231308

Antibody Information

URL: http://antibodyregistry.org/AB_2231308

Proper Citation: Santa Cruz Biotechnology Cat# sc-283, RRID:AB_2231308

Target Antigen: ErbB-4 (C-18)

Host Organism: mouse

Clonality: polyclonal

Comments: Discontinued: 2016; validation status unknown check with seller; recommendations: IgY Immunohistochemistry; Immunoprecipitation; Flow Cytometry; Western Blot; Immunocytochemistry; Immunofluorescence; ELISA; WB, IP, IF, IHC(P), FCM, ELISA

Antibody Name: ErbB-4 (C-18)

Description: This polyclonal targets ErbB-4 (C-18)

Target Organism: rat, mouse, human

Antibody ID: AB_2231308

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-283

Record Creation Time: 20250819T230150+0000

Record Last Update: 20250820T040412+0000

Ratings and Alerts

No rating or validation information has been found for ErbB-4 (C-18).

Warning: Discontinued: 2016

Discontinued: 2016; validation status unknown check with seller; recommendations: IgY Immunohistochemistry; Immunoprecipitation; Flow Cytometry; Western Blot; Immunocytochemistry; Immunofluorescence; ELISA; WB, IP, IF, IHC(P), FCM, ELISA

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Navarro-Gonzalez C, et al. (2021) Nrg1 haploinsufficiency alters inhibitory cortical circuits. *Neurobiology of disease*, 157, 105442.

Wang Z, et al. (2020) Cell Lineage-Based Stratification for Glioblastoma. *Cancer cell*, 38(3), 366.

Tanga N, et al. (2019) The PTN-PTPRZ signal activates the AFAP1L2-dependent PI3K-AKT pathway for oligodendrocyte differentiation: Targeted inactivation of PTPRZ activity in mice. *Glia*, 67(5), 967.

Urbanska M, et al. (2019) GSK3?? activity alleviates epileptogenesis and limits GluA1 phosphorylation. *EBioMedicine*, 39, 377.